Jeff Meacham

I wasn't sure what drives the investment priorities, whether it's the drug or the indication, and if there's a clear path to labeling claim

would you characterize it as more consumer-centric through LillyDirect? Or should we think about it as a more typical pharma launch with PBM and payer negotiations being really critical on day 1

can you talk about how the GI adverse event rates changed over the course of the studies?

Would these be a tipping point on broader reimbursement or access? I mean it's clear you have a benefit there